Business Context and Reporting Period
This Form 10-Q covers the quarterly and nine-month periods ended September 30, 2000, for Eli Lilly & Co, a pharmaceutical company headquartered in Indianapolis, Indiana. The company operates primarily in one significant business segment: pharmaceutical products for humans, with a non-material animal health division. The reporting period reflects strong growth in newer product lines offset by declining sales of legacy products, particularly Prozac, due to patent litigation and generic competition.
Key Financial Metrics
| Metric | Q3 2000 | Q3 1999 | 9M 2000 | 9M 1999 |
|---|---|---|---|---|
| Net Sales | $2,811.9M | $2,585.2M | $7,884.5M | $7,182.4M |
| Gross Margin | 82.6% | 78.8% | 81.1% | 78.7% |
| Income from Continuing Ops | $778.8M | $732.6M | $2,290.5M | $1,760.4M |
| Net Income | $778.8M | $732.6M | $2,290.5M | $1,934.7M |
| Diluted EPS (Continuing Ops) | $0.71 | $0.67 | $2.09 | $1.59 |
| Cash & Equivalents | $3,116.2M | N/A | N/A | N/A |
| Total Debt | $2,830.4M | N/A | N/A | N/A |
| Operating Cash Flow (9M) | N/A | N/A | $2,651.6M | $1,668.5M |
Note: Total Debt is the sum of Short-term borrowings ($45.0M) and Long-term debt ($2,785.4M) as of September 30, 2000.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 9% in Q3 2000 and 10% for the nine-month period compared to 1999. Growth was driven by volume increases (10% in Q3, 12% in 9M) and price increases (1% in Q3), partially offset by unfavorable exchange rates (-2%).
- Product Performance:
- Growers: Zyprexa (+28% Q3), Gemzar (+30% Q3), Evista (+53% Q3), and Diabetes care products (+14% Q3) led sales growth.
- Decliners: Prozac/Sarafem combined sales decreased 1% in Q3 and 3% in 9M. Anti-infectives declined 21% in Q3 due to competitive pressures. ReoPro sales fell 9% in Q3.
- Profitability: Gross margins improved significantly (82.6% in Q3 vs. 78.8% in Q3 1999) due to favorable product mix. Operating expenses increased 15% in Q3, driven by higher R&D ($506.1M) and marketing spend.
- Unusual Items:
- 2000: A one-time gain of $214.4M was recognized from the sale of Kinetra LLC and subsequent WebMD stock sales.
- 1999: Included a $67.8M gain on Lorabid rights, a $150M charitable contribution charge, and a $61.4M asset impairment charge.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Full Year 2000: Management anticipates low double-digit sales growth and EPS growth of approximately 16% over normalized 1999 earnings ($2.28/share). Gross margin improvement is expected to exceed 150 basis points.
- 2001-2002 Outlook: The company expects single-digit sales and EPS growth for 2001 and 2002, accelerating to double-digit growth in 2003. This outlook assumes a "very substantial decline" in U.S. Prozac sales following the entry of generic fluoxetine in August 2001.
- Share Repurchases: A $3 billion share repurchase program was announced in March 2000. Approximately 11.2 million shares were repurchased in the first nine months of 2000 for $775 million.
Risks and Contingencies
- Prozac Patent Litigation: The Court of Appeals upheld the 2001 compound patent but invalidated the 2003 method-of-use patent. The company is petitioning for a rehearing. If generic fluoxetine enters the U.S. market in August 2001, Prozac sales (approx. 21% of consolidated sales in 9M 2000) are expected to decline sharply.
- Product Liability: The company faces numerous lawsuits regarding DES and Prozac. Accruals for estimated exposure are maintained, with the majority of defense costs covered by insurance.
- Environmental Liabilities: Gross accruals for Superfund and remediation costs were approximately $151.8 million, with estimated insurance recoverables of $91.7 million.
- Drug Reimportation: New legislation signed in October 2000 potentially allows reimportation of prescription drugs, which could materially adversely affect results if widespread.
Investor Verification Checklist
- Prozac Patent Status: Verify the outcome of the petition for rehearing regarding the 2003 method-of-use patent and the likelihood of FDA granting market exclusivity until August 2001.
- Generic Competition Timeline: Confirm the exact entry date of generic fluoxetine in the U.S. market and the number of generic entrants.
- Product Mix Sustainability: Assess the growth trajectory of Zyprexa, Evista, and Gemzar to ensure they can offset the projected Prozac decline in 2001-2002.
- Legal Accruals: Review the adequacy of accruals for product liability (DES/Prozac) and environmental liabilities given the uncertainty of litigation outcomes.
- Reimportation Impact: Monitor regulatory developments regarding the drug reimportation law and its potential impact on pricing and sales volumes.